medigraphic.com
ISSN 1405-1710 (Print)

2013, Number 2

<< Back Next >>

Rev Cent Dermatol Pascua 2013; 22 (2)

Toll-like receptors in dermatology

Alcalá PD, Gómez MVM, Jurado SF

Language: Spanish
References: 34
Page: 56-62
PDF size: 187.67 Kb.


ABSTRACT

With the study of TLR over the time, we know that they are involved in an endless number of dermatological conditions including: acne, rosacea, psoriasis, atopic dermatitis, SLE, mycosis fungoide, syphilis, leprosy, Candida, pyoderma viral, cancer, to name a few, and also in the developing new therapeutic lines. The Toll like receptors represent a group of pattern-recognition receptors, which have been widely studied as an essential component of the innate and adaptative immune response, both infectious and non-infectious entities. Currently about 15 TLRs have been described in mammalian; although, only 10 are related in humans. The skin, being the first organ of defense against the external environment; the TLRs are expressed in a variety of skin cells, encouraging the immune response of this defense line.


REFERENCES

  1. Miller LS, Modlin RL. Toll-like receptors in the skin. Semin Immunopathol. 2007; 29: 15-26.

  2. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptative immunity. Nature. 1997; 338: 394-397.

  3. Lemaitre B, Nicholas E, Michaut L et al. The dorso ventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996; 86: 973-983.

  4. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol. 2006; 117: 979-987.

  5. Valins W, Amini S, Berman B. The expression of Toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical Toll-like receptor modulators. J Clin Aesthet Dermatol. 2010; 3: 20-29.

  6. Vanessa P, Anthony A, Toll-like receptors and dermatology, review. International Journal of Dermatology. 2009; 48: 558-570.

  7. Lebre MC, van der Aar AM, van BL, van Capel TM, Schuitemaker JH, Kapsenberg ML. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol. 2007; 127: 331-341.

  8. Renn CN, Sanchez DJ, Ochoa MT, Legaspi AJ, Oh CK, Liu PT. TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response. J Immunol. 2006; 177: 298-305.

  9. Krutzik SR, Tan B, Li H, Ochoa MT, Liu PT, Sharfstein SE. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med. 2005; 11: 653-660.

  10. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006; 311: 1770-1773.

  11. Kulka M, Metcalfe DD. TLR3 activation inhibits human mast cell attachment to fibronectin and vitronectin. Mol Immunol. 2006; 43: 1579-1586.

  12. Faure E, Equils O, Sieling PA, Thomas L, Zhang FX, Kirschning CJ. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem. 2000; 275: 11058-11063.

  13. Caron G, Duluc D, Fremaux I, Jeannin P, David C, Gascan H. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol. 2005; 175: 1551-1557.

  14. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005; 202: 1171-1177.

  15. Proost P, Vynckier AK, Mahieu F, Put W, Grillet B, Struyf S, Wuyts A. Microbial Toll-like receptor ligands differentially regulate CXCL10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFNgamma and provide a mechanism for enhanced synovial chemokine levels in septic arthritis. Eur J Immunol. 2003; 33: 3146-3153.

  16. Creely SJ, McTernan PG, Kusminski CM, Fisher FM, Khanolkar M, Evans M. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2006. DOI 10.1152/ajpendo.00302.2006

  17. Liu T, Xu ZZ, Park CK et al. Toll-like receptor 7 mediates pruritus. Nat Neurosci. 2010; 13: 1460-1462.

  18. Wang JF, Hori K, Ding J et al. Toll-like receptors expressed by dermal fibroblasts contribute to hypertrophic scarring. J Cell Physiol. 2011; 226: 1265-1273.

  19. Sato T, Yamamoto M, Shimosato T, Klinman DM. Accelerated wound healing mediated by activation of Toll-like receptor 9. Wound Repair Regen. 2010; 18: 586-593.

  20. Curry JL, Qin JZ, Bonish B, Carrick R, Bacon P, Panella J. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med. 2003; 127: 178-186.

  21. Kang TJ, Lee SB, Chae GT. A polymorphism in the Toll like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine. 2002; 20: 56-62.

  22. Krutzik SR, Ochoa MT, Sieling PA, Uematsu S, Ng YW, Legaspi A. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med. 2003; 9: 525-532.

  23. Oliveira RB, Ochoa MT, Sieling PA et al. Expression of Toll-like receptor 2 on human Schwann cells: a mechanism of nerve damage in leprosy. Infect Immun. 2003; 71: 1427-1433.

  24. Kim J, Ochoa MT, Krutzik SR et al. Activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002; 169: 1535-1541.

  25. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002; 169: 1535-1541.

  26. Moors MA, Li L, Mizel SB. Activation of interleukin-1 receptor-associated kinase by gram-negative flagellin. Infect Immun. 2001; 69: 4424-4429.

  27. Singh SK, Girschick HJ. Toll-like receptors in Borrelia burgdorferi-induced inflammation. Clin Microbiol Infect. 2006; 12: 705-717.

  28. Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K, Klotz M, Werfel T. The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol. 2004; 113: 565-567.

  29. Lovgren T, Eloranta ML, Bave U et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid release by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004; 50: 1861-1872.

  30. Ghosh TK, Mickelson DJ, Fink J et al. Toll-like receptor(TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Cell Immunol. 2006; 243: 48-57.

  31. Vabulas RM, Wagner H, Schild H. Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol. 2002; 270: 169-184.

  32. Heil F, Ahmad-Nejad P, Hemmi H et al. The Toll-like receptor 7 (TLR7) specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003; 3: 2987-2997.

  33. Sun S, Rao NL, Venable J et al. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007; 6: 223-235.

  34. Hofmann MA, Kors C, Audring H. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother. 2008; 31: 520-527.




2020     |     www.medigraphic.com